论文部分内容阅读
1959年Thomas首先对一例应用大剂量放射治疗的白血病患者进行人胎肝细胞输注,开创了胎肝细胞在血液病领域中的临床研究.越来越多的报道说明,胎肝细胞悬液治疗再生障碍性贫血、白血病、免疫缺陷病、放射病等疗效显著.迄今为止,国外尚无用人胎肝细胞治疗肝病的报道.国内在动物实验的基础上由陈成伟于1985年初首先将其用于治疗急性重型肝炎,继之用于慢性活动型肝炎(慢活肝),均获得可喜的初步疗效,并迅速在国内得到推广.现就人胎肝细胞悬液治疗病毒性肝炎的现状作一综述.
In 1959, Thomas first conducted a human fetal liver cell infusion on a case of leukemia patients using high-dose radiation therapy, starting a clinical study of fetal liver cells in the field of hematology.More and more reports indicate that fetal liver cell suspension treatment Aplastic anemia, leukemia, immunodeficiency disease, radiation sickness and other significant effect.So far, there is no report of treatment of liver disease with human fetal liver cells abroad.On the basis of animal experiments in China by Chen Chengwei first used in early 1985 for the treatment of acute Severe hepatitis, followed by chronic active hepatitis (slow living liver), are gratifying initial efficacy, and promptly be promoted in the country.We now review the status of human fetal liver cell suspension for the treatment of viral hepatitis.